Preclinical pharmacokinetic evaluation of β-lapachone: Characteristics of oral bioavailability and first-pass metabolism in rats

Biomolecules and Therapeutics

Volumn 23, Issue 3, 2015, Pages 296-300

  Kim, Iksoo ^a   Kim, Hyeongmin ^a   Ro, Jieun ^a   Jo, Kanghee ^a   Karki, Sandeep ^a   Khadka, Prakash ^a   Yun, Gyiae ^a   Lee, Jaehwi ^a  

^a Chung Ang University   (South Korea)

Author keywords

Bioavailability; Metabolism; Pharmacokinetics; Preclinical; Lapachone

Indexed keywords

BETA LAPACHONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LARGE INTESTINE; LIVER HOMOGENATE; LIVER METABOLISM; MALE; NONHUMAN; RAT; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS;

EID: 84928993766     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2015.029     Document Type: Article

References (14)

1. Blanco, E., Bey, E. A., Khemtong, C., Yang, S. G., Setti-Guthi, J., Chen, H., Kessinger, C. W., Carnevale, K. A., Bornmann, W. G., Boothman, D. A. and Gao, J. (2010) Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 70, 3896-3904.
2. Byun, S. J., Son, Y., Cho, B. H., Chung, H.-T. and Pae, H.-O. (2013) β-Lapachone, a substrate of NAD(P)H:quinone oxidoreductase, induces anti-inflammatory heme oxygenase-1 via AMP-activated protein kinase activation in RAW264.7 macrophages. J. Clin. Biochem. Nutr. 52, 106-111.
3. Crooke, R. M., Graham, M. J., Martin, M. J., Lemonidis, K. M., Wyrzykiewiecz, T. and Cummins, L. L. (2000) Metabolism of antisense oligonucleotides in rat liver homogenates. J. Pharmacol. Exp. Ther. 292, 140-149.
4. Dong, Y., Chin, S. F., Blanco, E., Bey, E. A., Kabbani, W., Xie, X. J., Bornmann, W. G., Boothman, D. A. and Gao, J. (2009) Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin. Cancer Res. 15, 131-139.
5. Hao, H., Wang, G., Cui, N., Li, J., Xie, L. and Ding, Z. (2007) Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr. Drug Metab. 8, 137-149.
6. Koo, T. S., Kim, D. H., Ahn, S. H., Kim, K. P., Kim, I. W., Seo, S. Y., Suh, Y. G., Kim, D. D., Shim, C. K. and Chung, S. J. (2005) Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: evidence for extrahepatic metabolism. J. Pharm. Sci. 94, 2187-2197.
7. Lee, J. H., Cheong, J., Park, Y. M. and Choi, Y. H. (2005) Down-regulation of cyclooxygenase-2 and telomerase activity by β-lapachone in human prostate carcinoma cells. Pharmacol. Res. 51, 553-560
8. Miao, X. S., Song, P., Savage, R. E., Zhong, C., Yang, R.-Y., Kizer, D., Wu, H., Volckova, E., Ashwell, M. A., Supko, J. G., He, X. and Chan, T. C. (2008) Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; β-lapachone) in whole blood. Drug Metab. Dispos. 36, 641-648.
9. Nasongkla, N., Wiedmann, A. F., Bruening, A., Beman, M., Ray, D., Bornmann, W. G., Boothman, D. A. and Gao J. (2003) Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharm. Res. 20, 1626-1633.
10. Park, M.-T., Song, M.-J., Lee, H., Oh, E.-T., Choi, B.-H., Jeong, S.-Y., Choi, E.-K. and Park, H.J. (2011) β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells. PLoS One 6, e25976.
11. Savage, R. E., Tyler, A. N., Miao, X.-S. and Chan, T. C. K. (2008) Identification of a novel glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, β-lapachone) in mammals. Drug Metab. Dispos. 36, 753-758.
12. Subramanian, N., Subhabrata, R., Ghosal, S. K., Bhadra, R. and Moulik, S. P. (2004) Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol. Pharm. Bull. 27, 1993-1999.
13. Takano, R., Furumoto, K., Shiraki, K., Takata, N., Hayashi, Y., Aso, Y. and Yamashita, S. (2008) Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm. Res. 25, 2334-2344.
14. Tzeng, H. P., Ho, F. M., Chao, K. F., Kuo, M. L., Lin-Shiau, S. Y. and Liu, S. H. (2003) β-Lapachone reduces endotoxin-induced macrophage activation and lung edema and mortality. Am. J. Respir. Crit. Care Med. 168, 85-91.